Objective:

To discuss the evolving landscape of obesity care and the role of GLP-1 receptor agonists in multimodal treatment strategies, emphasizing their integration with surgical options.

Key Findings:

• GLP-1 medications have increased patient engagement in obesity treatment, leading to more patients seeking care.
• Less than 1% of eligible patients undergo bariatric surgery, highlighting a significant gap in treatment access.
• Oral GLP-1s offer new options but have specific dosing challenges that may affect adherence.
• Surgery remains essential for patients who do not achieve sufficient weight loss with medications, underscoring the need for a comprehensive treatment approach.

Interpretation:

The introduction of GLP-1s is reshaping obesity care, encouraging a more comprehensive approach that integrates both medication and surgery, reflecting a shift in treatment philosophy.

Limitations:

• Current GLP-1 medications result in 10% to 20% total body weight loss, which may not be sufficient for all patients, particularly those with higher BMIs.
• Oral formulations have specific dosing requirements that may complicate adherence, potentially impacting treatment effectiveness.

Conclusion:

A multimodal approach to obesity treatment, incorporating both GLP-1s and surgical options, is essential for effective patient care.